https://staging.moocwiki.org/index.php?action=history&feed=atom&title=Aging%2FResearch_reports%2F2026-10-01
Aging/Research reports/2026-10-01 - Versionsgeschichte
2026-10-04T01:41:14Z
Versionsgeschichte dieser Seite in MOOCsWiki Staging
MediaWiki 1.46.0
https://staging.moocwiki.org/index.php?title=Aging/Research_reports/2026-10-01&diff=60847&oldid=prev
Glanz: Aging daily 30aee9fa0c2b46ee8264e9d4d18878b6 b2be8158cdd2
2026-10-01T09:31:07Z
<p>Aging daily 30aee9fa0c2b46ee8264e9d4d18878b6 b2be8158cdd2</p>
<p><b>Neue Seite</b></p><div>__NOTOC__<br />
<div class="aging-research-world aging-journal" lang="en"><br />
<div class="aj-masthead"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aging-languages" role="navigation" aria-label="Sprache / Language"><span class="aging-language" title="Deutsch">[[Altern/Forschungsberichte/2026-10-01|🇩🇪]]</span><span class="aging-language" title="English">[[Aging/Research reports/2026-10-01|🇬🇧]]</span></div></div><br />
<div class="aj-context"><strong>An evolving AI research project</strong>[[Aging/About the project|Background · goals · methods]]<span>Updated 1 Oct 2026</span></div><br />
<h1>Protein degradation with functional evidence?</h1><br />
<div class="aj-deck">Research report · 1 October 2026 · Autophagy, tau and function</div><br />
<div class="aj-article"><br />
<br />
<div class="aj-kicker">The decisive question</div><br />
== Can targeted protein degradation preserve function without leaving active fragments? ==<br />
'''Today's decision:''' Antibody–LC3 coupling enters the approaches list as preclinical comparator AG-A11. A published functional finding merits follow-up. It confirms neither our TIMP2 hypothesis nor a treatment for human aging. AG-C03 / AG-T01 remains '''🔵 Level 2, low confidence'''. The added literature is '''⚪ Level 1'''. Project level and scientific evidence are separate assessments.<br />
<br />
== What the new study actually connects ==<br />
Guo et al., published '''26 August 2026''', engineered autophagy receptors by coupling antibodies to LC3A to direct selected proteins towards degradation. Two experimental routes must remain separate:<br />
<br />
* '''Tau / small extracellular vesicles:''' preclinical pathology findings, including intravenously treated TauP301S mice.<br />
* '''TDP-43 / AAV:''' reduced insoluble protein and improved motor performance are reported in TDP-43ΔNLS mice. The rotarod finding belongs to this route.<br />
<br />
Source: [https://www.nature.com/articles/s41551-026-01774-9 Guo et al., Nature Biomedical Engineering, DOI 10.1038/s41551-026-01774-9]. We inspected the public publisher preview, figures and linked numerical source data. Complete methods were unavailable; critical appraisal therefore remains provisional. Technology-related patent interests are disclosed. No independent replication was verified.<br />
<br />
== Recalculation: what do the published points support? ==<br />
Our '''descriptive recalculation''' of the published table is not a new study: sheet '''Fig4e''', '''B2:B8''' versus '''C2:C8''', seven values each. Figure 4e labels the endpoint rotarod latency to fall in seconds.<br />
<br />
* Anti-TDP43: mean '''18.14 s''', median '''12.00 s''', observed range '''7.50–47.25 s'''.<br />
* Anti-TDP43-LC3A: mean '''54.61 s''', median '''68.25 s''', range '''9.25–93.25 s'''.<br />
* Difference of means: Σ(LC3A values)/7 − Σ(comparator values)/7 = '''36.46 s'''.<br />
* Sensitivity: across all 49 combinations omitting one value from each group, mean differences range from '''28.25 to 48.88 s'''. This is '''not a confidence interval'''.<br />
<br />
The direction does not depend on a single tabulated value. Wide dispersion, small counts and unresolved experimental units, allocation and measurement timing prevent robust new inference here. No pairing was assumed, no new p-value calculated, and no human efficacy estimated. Dose, duration, baseline impairment and preservation of normal protein function still require appraisal.<br />
<br />
[https://media.springernature.com/original/springer-static/esm/art%3A10.1038%2Fs41551-026-01774-9/MediaObjects/41551_2026_1774_MOESM5_ESM.xlsx Original source data for Figures 2–7] · [https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41551-026-01774-9/MediaObjects/41551_2026_1774_Fig4_HTML.png Figure 4]. Empty cells were not converted to zero; both compared groups contain seven numerical entries.<br />
<br />
== Countercheck: a detected peptide is not an identified active molecule ==<br />
The deeper audit of Karabova et al. ('''6 April 2026''', AG-D01) separates peptide detection from seeding activity. Mass spectrometry reported in the main text maps peptides to sequence regions. It does not thereby establish the connected boundaries of an intact, seeding-competent fragment. Activity in a mixture cannot be assigned to an individual detected peptide.<br />
<br />
'''Our conditional inference:''' If FRET activity is divided by ELISA-detected tau, a truncation-related reduction in ELISA response could increase that ratio. Whether such bias occurs and how large it might be have not been established here. This does not refute observed activity; it limits claims about activity per actual tau mass. Supplementary peptide tables and antibody epitopes could not be directly audited. [https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71337 Primary source, sections 3.5–3.8; DOI 10.1002/alz.71337].<br />
<br />
== Evidence and the next executable step ==<br />
* '''Established information:''' Publication dates, distinct experimental routes and recalculated table values. No established reversal of aging.<br />
* '''Promising indication:''' Connecting targeted protein control to a functional endpoint merits further scrutiny.<br />
* '''Experimental model findings:''' Reported protein and motor outcomes come from disease models; they do not establish human efficacy.<br />
* '''Hypothesis:''' Selective degradation might help if active residual cargo, loss of normal protein function and synaptic damage are avoided. Today's comparison does not establish this complete chain.<br />
<br />
'''Next executable check:''' Assess the already identified related primary study DOI 10.1126/scitranslmed.aea4205 for target protein, delivery, model, functional endpoint, duration and shared data/research groups. Compare Guo's study against it rather than combining positive results from different systems into one supposedly confirmed chain. Guo's methods for randomization, blinding, experimental units and time course remain open. A sustained lack of functional benefit or loss of normal protein function would weaken the corresponding benefit hypothesis.<br />
<br />
Axolotl regeneration remains a separate repair route; no new axolotl source was assessed today. The approaches will only be connected where a mechanistic link is supported. [[Aging/Approaches to aging|Expanded approaches list]] · [[Aging/Evidence chain|Cumulative evidence chain]].<br />
<br />
'''Search and teaching:''' Retrieval and analysis '''1 October 2026'''; one new DOI (AG-D03), one deeper existing-source audit (AG-D01). Targeted DOI/title searches found no matching correction or retraction notice; this was not a comprehensive registry audit. Coverage remains selective. Measurement and dependency appraisal deepen AG-P17–20; no additional wishlist assignment before complete methodological review. [[Aging/Research colloquium|Professor research colloquium and existing learning packages]]. No laboratory experiments, independent experimental replication or self-medication advice.<br />
<br />
</div><br />
<div class="aj-section-title"><h2>Continue exploring</h2></div><div class="aj-tiles"><div class="aj-tile"><div class="aj-thumb">[[File:Bovine Pulmonary Artery Endothelial Cells Fluorescent Image.jpg|120px|frameless|link=Aging/Approaches to aging|alt=Fluorescence micrograph of bovine endothelial cells with labeled nuclei, actin and mitochondria.]]</div><div><div class="aj-tile-title">[[Aging/Approaches to aging|Approaches to aging]]</div><div class="aj-tile-desc">Evidence and functional outcomes</div></div></div><div class="aj-tile"><div class="aj-thumb aj-type-thumb">[[Aging/Evidence chain|→]]</div><div><div class="aj-tile-title">[[Aging/Evidence chain|Evidence chain]]</div><div class="aj-tile-desc">How studies generate new questions</div></div></div><div class="aj-tile"><div class="aj-thumb">[[File:DNA double helix.svg|120px|frameless|link=Aging/Research colloquium|alt=Schematic illustration of a DNA double helix.]]</div><div><div class="aj-tile-title">[[Aging/Research colloquium|Research colloquium]]</div><div class="aj-tile-desc">16 foundation assignments + 4 new deep dives</div></div></div></div><br />
<div class="aj-footer"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aj-context">[[Aging|Project overview]][[Aging/About the project|Goals & methods]][[Aging/Evidence chain|Evidence chain]]</div><div class="aj-meta">AI-assisted literature research and model building. No laboratory or clinical studies conducted by this project. No personal treatment plans.</div><div class="aj-credits">Image credits · Illustrations, not project data: [https://commons.wikimedia.org/wiki/File:Axolotl_Portrait.jpg Axolotl] — LoKiLeCh ([https://creativecommons.org/licenses/by-sa/3.0/ CC BY-SA 3.0]) · [https://commons.wikimedia.org/wiki/File:XBio_illustration_%E2%80%93_Neuron.png Neuron] — explorebiology (Explore Biology) ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0]) · [https://commons.wikimedia.org/wiki/File:DNA_double_helix.svg DNA] — Biochemlife ([https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0]) · [https://commons.wikimedia.org/wiki/File:Bovine_Pulmonary_Artery_Endothelial_Cells_Fluorescent_Image.jpg Bovine endothelial cells] — Erin Rod ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0])</div></div><br />
</div><br />
[[Category:Altern / Aging]]</div>
Glanz